Know Cancer

or
forgot password

Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial


Phase 2
18 Years
75 Years
Not Enrolling
Both
Non-small Cell Lung Cancer

Thank you

Trial Information

Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial


Inclusion Criteria:



- completely resected pathological stage IB or II NSCLC

- adequate haematological, renal and liver function and condition

Exclusion Criteria:

- previous chemo or radiotherapy for NSCLC

- bronchoalveolar cell subtype

- second active primary malignancy or serious concomitant medical disease

- difficulties with adequate follow-up

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Success of delivery treatment; data collected during chemotherapy treatment

Principal Investigator

Paul R. Germonpre, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Thoracic Oncology Group Antwerp

Authority:

Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment

Study ID:

TOGA 0501

NCT ID:

NCT00434668

Start Date:

December 2005

Completion Date:

November 2010

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • NSCLC
  • Adjuvant chemotherapy for completely resected NSCLC
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location